1.31
Cerus Corp stock is traded at $1.31, with a volume of 842.59K.
It is down -7.09% in the last 24 hours and down -1.50% over the past month.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
See More
Previous Close:
$1.41
Open:
$1.39
24h Volume:
842.59K
Relative Volume:
0.64
Market Cap:
$275.27M
Revenue:
$156.37M
Net Income/Loss:
$-37.49M
P/E Ratio:
-6.2381
EPS:
-0.21
Net Cash Flow:
$-47.77M
1W Performance:
-9.03%
1M Performance:
-1.50%
6M Performance:
-22.49%
1Y Performance:
-27.62%
Cerus Corp Stock (CERS) Company Profile
Name
Cerus Corp
Sector
Industry
Phone
(925) 288-6000
Address
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CERS
Cerus Corp
|
1.31 | 275.27M | 156.37M | -37.49M | -47.77M | -0.21 |
![]()
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-24 | Initiated | Craig Hallum | Buy |
Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
Oct-08-20 | Resumed | BTIG Research | Buy |
Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
Feb-26-20 | Initiated | BTIG Research | Buy |
Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
Aug-28-19 | Initiated | Stifel | Buy |
Aug-23-19 | Resumed | Stephens | Overweight |
Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
Dec-08-17 | Resumed | BTIG Research | Neutral |
Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
May-02-14 | Reiterated | MLV & Co | Buy |
Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
Mar-15-13 | Reiterated | MLV & Co | Buy |
Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
Nov-10-11 | Reiterated | MLV & Co | Buy |
Jun-03-11 | Initiated | Wedbush | Outperform |
Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp Stock (CERS) Latest News
Daily Market Movement: Cerus Corp (CERS) Sees a 6.82 Increase, Closing at 1.41 - DWinneX
26,884 Shares in Cerus Co. (NASDAQ:CERS) Purchased by Pallas Capital Advisors LLC - Defense World
Cerus Corporation Celebrates World Blood Donor Day 2025 - Yahoo Finance
Cerus at Goldman Sachs Conference: Pathogen Reduction Leadership - Investing.com
Cerus at Goldman Sachs Conference: Pathogen Reduction Leadership By Investing.com - Investing.com Canada
Cerus Corp shareholders approve equity plan amendment By Investing.com - Investing.com South Africa
Cerus Corp shareholders approve equity plan amendment - Investing.com
Sigyn Therapeutics (OTCMKTS:SIGY) & Cerus (NASDAQ:CERS) Head to Head Comparison - Defense World
Two Sigma Investments LP Acquires 326,605 Shares of Cerus Co. (NASDAQ:CERS) - Defense World
Mackenzie Financial Corp Acquires 17,704 Shares of Seanergy Maritime Holdings Corp. (NASDAQ:SHIP) - Defense World
3 Promising Penny Stocks With Market Caps Over $90M - Yahoo Finance
Cerus Management Takes Stage at Goldman Sachs Healthcare Conference: Key Updates Coming June 11 - Stock Titan
Cantor Fitzgerald maintains Cerus stock rating due to regulatory approvals By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Cerus stock rating due to regulatory approvals - Investing.com
Cerus to present new INTERCEPT Blood System data at ISBT Congress - Investing.com
Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan - Yahoo Finance
Breakthrough Phase 3 Results: New Clinical Data Shows INTERCEPT Blood System Success in Multiple Applications - Stock Titan
Cerus (CERS) Gains French and Swiss Regulatory Approvals for New Device | CERS Stock News - GuruFocus
Cerus gains regulatory nods for blood safety device in Europe - Investing.com
Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device - Business Wire
Cerus Co. (NASDAQ:CERS) Stake Boosted by Jane Street Group LLC - Defense World
When Should You Buy Cerus Corporation (NASDAQ:CERS)? - Yahoo Finance
Price T Rowe Associates Inc. MD Buys 34,694 Shares of Cerus Co. (NASDAQ:CERS) - Defense World
Stifel Financial Corp Grows Stock Position in Cerus Co. (NASDAQ:CERS) - Defense World
Raymond James Financial Inc. Acquires Shares of 244,073 Cerus Co. (NASDAQ:CERS) - Defense World
Closing Strong: Cerus Corp (CERS) Ends at 1.25, Down -3.85 from Last Close - DWinneX
Cerus Corporation Announces First Quarter 2025 Financial Results - ADVFN
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
JPMorgan Chase & Co. Grows Stock Holdings in Cerus Co. (NASDAQ:CERS) - Defense World
Cerus Corporation (NASDAQ:CERS) Just Reported, And Analysts Assigned A US$4.25 Price Target - Yahoo Finance
Cerus Corporation (NASDAQ:CERS) Q1 2025 Earnings Call Transcript - Insider Monkey
Cerus Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Cerus: Q1 Earnings Snapshot - MySA
Earnings call transcript: Cerus Q1 2025 revenue up, stock dips post-earnings - Investing.com
CERUS CORP SEC 10-Q Report - TradingView
Cerus Corp Reports Q1 2025 Earnings: EPS Matches Estimate at -$0 - GuruFocus
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Cerus Corp (CERS) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Cerus Corp (CERS) deserves deeper analysis - uspostnews.com
Trading Day Review: Cerus Corp (CERS) Loses Momentum, Closing at 1.34 - DWinneX
Geode Capital Management LLC Grows Stock Position in Cerus Co. (NASDAQ:CERS) - Defense World
Cerus Corp (NASDAQ:CERS) Price Forecast For The Next 12 Months Is Set At 5. - Marketing Sentinel
Cerus Corp (CERS) deserves closer scrutiny - uspostnews.com
Vanguard Group Inc. Has $16.04 Million Stock Holdings in Cerus Co. (NASDAQ:CERS) - Defense World
Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 - Yahoo Finance
Lobbying Update: $40,000 of CERUS CORPORATION lobbying was just disclosed - Nasdaq
After losing 21% in the past year, Cerus Corporation (NASDAQ:CERS) institutional owners must be relieved by the recent gain - simplywall.st
Raymond James Financial Inc. Purchases Shares of 244,073 Cerus Co. (NASDAQ:CERS) - Defense World
Cerus stock touches 52-week low at $1.19 amid market challenges - Investing.com
Virtu Financial LLC Takes $33,000 Position in Cerus Co. (NASDAQ:CERS) - Defense World
How Are Things Looking For Cerus Corp (NASDAQ: CERS) For The Short Term? - stocksregister.com
Cerus Corp Stock (CERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):